GlassScriptPhysician profile
Veronica Caudill-Engle
NPI 1144513276
$516.15
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $113 · 2021: $183 · 2022: $30.23 · 2023: $68.37 · 2024: $15.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $96.68 | 2019-2022 | |
| Abbvie INC. | $65.13 | 2023-2024 | Vraylar, Dalvance |
| Astrazeneca Pharmaceuticals LP | $53.42 | 2019-2020 | |
| Novo Nordisk INC | $47.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.92 | 2021-2023 | |
| Grifols USA, LLC | $36.49 | 2019 | |
| Daiichi Sankyo INC. | $30.58 | 2020 | |
| Pfizer INC. | $28.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.54 | 2020-2021 | |
| Lilly USA, LLC | $22.58 | 2020-2021 | |
| Amgen INC. | $18.95 | 2021 | |
| Amarin Pharma, INC. | $15.38 | 2019 | |
| Radius Health, INC. | $14.76 | 2020 | |
| Nestle Healthcare Nutrition INC. | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Caudill-Engle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.